share_log

Cantor Fitzgerald Reiterates Overweight on Lineage Cell Therapeutics, Maintains $6 Price Target

Cantor Fitzgerald Reiterates Overweight on Lineage Cell Therapeutics, Maintains $6 Price Target

坎託·菲茨傑拉德重申增持Lineage Cell Therapeutics,維持6美元的目標股價
Benzinga ·  2023/07/25 07:56

Cantor Fitzgerald analyst Kristen Kluska reiterates Lineage Cell Therapeutics (AMEX:LCTX) with a Overweight and maintains $6 price target.

Cantor Fitzgerald分析師Kristen Kluska重申Lineage Cell Treateutics(AMEX:LCTX)增持股票,並維持6美元的目標價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論